Drug intelligence / Profile preview

RO7058584

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Ophthalmic

Overview

RO7058584 is a small molecule drug developed by Roche for treating primary open-angle glaucoma and ocular hypertension. It was formulated as a topical eye drop intended to lower intraocular pressure. The mechanism of action is undisclosed. Clinical development reached Phase 1, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with primary open-angle glaucoma or ocular hypertension. Development has been discontinued for these indications[1][2][5].

Other names: RO 7058584RO7058584RO-7058584RG 7945RG7945RG-7945

Beyond the preview

Go deeper on RO7058584.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO7058584.

Explore the full profile